Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 12/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | WNT3 | P56703 | 1/20 | 0.39 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1722375 | 0.88 | CACNA1B (0.49) | CYP3A4CACNA1BNR1I2CYP2C19CYP2D6 | |
| SCHEMBL7927653 | 0.87 | NR1H2 (0.40) | STSTGFBR1WNT3SFRP1 | |
| SCHEMBL2188839 | 0.85 | CACNA1B (0.52) | CYP3A4CACNA1BNR1I2STSCYP2C19 | |
| SCHEMBL3035528 | 0.82 | CYP3A4 (0.52) | CYP3A4CACNA1BNR1I2STSRORC | |
| SCHEMBL2188014 | 0.81 | CYP3A4 (0.52) | CYP3A4CACNA1BNR1I2STSRORC | |
| SCHEMBL2191964 | 0.81 | CACNA1B (0.62) | CYP3A4CACNA1BNR1I2STSTGFBR1 | |
| SCHEMBL2189917 | 0.78 | CYP3A4 (0.45) | CYP3A4CACNA1BNR1I2CYP2C19CYP2D6 | |
| SCHEMBL26848604 | 0.74 | CHRM2 (0.39) | RORC | |
| SCHEMBL29081264 | 0.74 | CHRM2 (0.39) | RORC | |
| SCHEMBL26848640 | 0.74 | CHRM2 (0.39) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CHAKRAVARTY PRASUN K | 2011-07-14 | — | — | US | disclosed |
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CHAKRAVARTY PRASUN K | 2011-07-14 | — | — | US | disclosed |
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CHAKRAVARTY PRASUN K | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, TRPA1, CACNA1D | CYP3A4 939/4885CACNA1B 23/4885NR1I2 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.